Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke

US FDA issues 17 observations for Biocon Biologics sites

The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools

A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert

India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved

Biological E. announces CDSCO recommendation of its infant’s vaccine

Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)

Moderna sues Pfizer, BioNTech for mRNA patent infringement

Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016

Qdenga approved in Indonesia for use regardless of prior dengue exposure

Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age

Collective efforts needed to make India a global healthcare leader: Dr Mandaviya

It is high time that India assumed a leadership role in healthcare.

Aurobindo Pharma Foundation and Rotary Clubs donated 800 bicycles

The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive

Lupin and I'rom signs licensing agreement for Denosumab biosimilar for Japan

Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients